In January, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway to treat Alzheimer’s disease. Nathaniel Chin, MD, recently interviewed Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to inform people about the research behind the new Alzheimer’s treatment, the drug's benefits and risks, and more.
Carey Gleason, PhD, MS, and her research team’s African Americans Fighting Alzheimer's in Midlife (AA-FAIM) study is entering its second, five-year cycle and they are focused on making Alzheimer’s research more inclusive.
Maria Mora Pinzon, MD, MS, FACPM, was recently appointed to assistant professor on the tenure track in the Division of Geriatrics and Gerontology at the University of Wisconsin School of Medicine and Public Health, where she will continue working with the Wisconsin Alzheimer’s Institute and expand her research program.
On the latest episode of the podcast, Dementia Matters, host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials.
Nathaniel Chin, MD, joined host Rob Ferrett on the call-in program “Central Time” on The Ideas Network of Wisconsin Public Radio. Chin discussed the recent FDA approval of the drug Leqembi (lecanemab) to help with early Alzheimer's and answered callers’ questions.
Cynthia Carlsson, MD, MS, was recently interviewed by CBS 58 News in Milwaukee about the U.S. Food and Drug Administration (FDA) approval of Leqembi (lecanemab), which showed a reduction of clinical decline in a study of people with early Alzheimer’s disease.
On January 6, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.
Sanjay Asthana, MD, is the founding director of the Wisconsin Alzheimer’s Disease Research Center (ADRC) and an internationally renowned researcher and leader in the field of Alzheimer’s disease. The US Secretary of Health and Human Services and the Director of the National Institutes of Health (NIH) have invited Asthana, professor and Duncan G. and Lottie …
Ozioma Okonkwo, PhD, has been appointed to participate in a National Institute on Aging (NIA) Alzheimer’s and Alzheimer’s Association workgroup, establishing the definition and classification of Alzheimer’s disease.
Sterling Johnson, PhD, has been awarded a Vilas Distinguished Achievement Professorship, an appointment given to extraordinary members of the University of Wisconsin–Madison faculty. The award provides five years of flexible funding and recognizes distinguished scholarship and standout teaching and service efforts.